In 2007 a new pediatric regulation was put in place aimed at encouraging the development and marketing of drugs suitable for children in Europe.

The purpose of this regulation is:

In partnership with clinicians Advicenne is focusing on the treatment of neglected/orphan diseases of the central nervous system and certain renal disorders. These two treatment fields are cruelly short of drugs adapted to children.

ADVICENNE is, and will remain, above all and throughout its development a company committed to patients, more especially children who suffer from rare or neglected diseases, putting scientific innovation and medical excellence at the service of pediatrics.